MJA
MJA

Scientists in pyjamas: characterising the working arrangements and productivity of Australian medical researchers during the COVID‐19 pandemic

David G Chapman and Cindy Thamrin
Med J Aust 2020; 213 (11): . || doi: 10.5694/mja2.50860
Published online: 14 December 2020

Abstract

Objective: To characterise the working arrangements of medical research scientists and support staff in Australia during the COVID‐19 pandemic, and to evaluate factors (in particular: wearing pyjamas) that influence the self‐assessed productivity and mental health of medical institute staff working from home.

Design: Prospective cohort survey study, 30 April – 18 May 2020.

Setting, participants: Staff (scientists and non‐scientists) and students at five medical research institutes in Sydney, New South Wales.

Main outcome measures: Self‐assessed overall and task‐specific productivity, and mental health.

Results: The proportions of non‐scientists and scientists who wore pyjamas during the day were similar (3% v 11%; P = 0.31). Wearing pyjamas was not associated with differences in self‐evaluated productivity, but was significantly associated with more frequent reporting of poorer mental health than non‐pyjama wearers while working from home (59% v 26%; P < 0.001). Having children in the home were significantly associated with changes in productivity. Larger proportions of people with toddlers reported reduced overall productivity (63% v 32%; P = 0.008), and reduced productivity in writing manuscripts (50% v 17%; P = 0.023) and data analysis (63% v 23%; P = 0.002). People with primary school children more frequently reported reduced productivity in writing manuscripts (42% v 16%; P = 0.026) and generating new ideas (43% v 19%; P = 0.030). On a positive note, the presence of children in the home was not associated with changes in mental health during the pandemic. In contrast to established researchers, early career researchers frequently reported reduced productivity while working at home.

Conclusions: Our findings are probably applicable to scientists in other countries. They may help improve work‐from‐home policies by removing the stigma associated with pyjama wearing during work and by providing support for working parents and early career researchers.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Health and medicine in a pandemic year: moving from the “winter of despair” to the “spring of hope”

Nicholas J Talley
Med J Aust 2020; 213 (11): . || doi: 10.5694/mja2.50861
Published online: 14 December 2020

Despite a year of floods, fires and pestilence, we approach 2021 with optimism

It has been a strange and disturbing year. Here in Australia, we would usually now be looking forward to the long summer break, the barbeques and the parties, the leisure time at home. Many would be traveling overseas to visit friends and family. But these have not been normal times.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.




Correspondence: ntalley@mja.com.au

Acknowledgements: 

I thank the tireless efforts of the Editorial team throughout 2020, without which the quality and timely publication of our Journal in print and online would not be possible: our departing Head of Publishing Content, Lilia Kanna; our former Senior Deputy Medical Editor, Christine Gee; Deputy Medical Editors Francis Geronimo, Robyn Godding, Tania Janusic, Selina Lo, Wendy Morgan, Aajuli Shukla, and Zoë Silverstone; our Scientific and Structural Editors, Paul Foley, Graeme Prince, and Laura Teruel; our Consultant Biostatistician, Elmer Villanueva; our News and Online Editor, Cate Swannell; our Graphic Designer, Leilani Widya; and our Senior Publishing Coordinator, Kerrie Harding.

Competing interests:

A complete list of disclosures is available at https://www.mja.com.au/journ​al/staff/editor-chief-professor-nick-talley

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Enough seagulls! Rural and remote communities need local researchers living, walking and talking with locals

Ruth Stewart
Med J Aust 2020; 213 (11): . || doi: 10.5694/mja2.50857
Published online: 7 December 2020

Researchers who live and work in community can respond to local clinical questions and provide feedback to community on their findings

Australians enjoy some of the best health outcomes in the world1 and those benefits are concentrated in our urban centres. Australians who live in rural and remote Australia have poorer health than their urban peers. The more remote your residence, the shorter your life span and the greater the burden of disease carried by your community.2


  • Australian Government Department of Health, National Rural Health Commissioner, Canberra, ACT


Correspondence: NRHC@health.gov.au

Competing interests:

No relevant disclosures.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

The short to medium term benefits of the Australian colorectal cancer screening program

Sasha Taylor, Farhad Salimi, Arul Earnest, Alexander G Heriot, John R Zalcberg and Susannah Ahern
Med J Aust 2021; 214 (2): . || doi: 10.5694/mja2.50859
Published online: 7 December 2020

In Australia, colorectal cancer is the second most frequently diagnosed cancer and one of the most common causes of cancer‐related death.1 Evidence that bowel cancer screening reduces mortality through early detection and treatment2 led to the introduction in 2006 of the Australian National Bowel Cancer Screening Program (NBCSP), offering faecal occult blood testing. The NBCSP has been progressively rolled out, from covering those aged 55 or 65 years in 2006 to screening every two years for all Australians aged 50–74 years by 2020.3 During 2016–17, 41% of people invited to participate in screening did so.4 A recent review of the NBCSP found that the risk of death from colorectal cancer was lower for invitees, and that those who had cancer were diagnosed at an earlier stage of disease.5

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC
  • 2 Epworth HealthCare, Melbourne, VIC
  • 3 Peter MacCallum Cancer Institute, Melbourne, VIC
  • 4 University of Melbourne, Melbourne, VIC


Correspondence: susannah.ahern@monash.edu

Acknowledgements: 

The Binational Colorectal Cancer Audit is supported by the Colorectal Surgical Society of Australia and New Zealand (CSSANZ).

Competing interests:

No relevant disclosures.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

The 2020 special report of the MJA–Lancet Countdown on health and climate change: lessons learnt from Australia’s “Black Summer”

Ying Zhang, Paul J Beggs, Alice McGushin, Hilary Bambrick, Stefan Trueck, Ivan C Hanigan, Geoffrey G Morgan, Helen L Berry, Martina K Linnenluecke, Fay H Johnston, Anthony G Capon and Nick Watts
Med J Aust 2020; 213 (11): . || doi: 10.5694/mja2.50869
Published online: 3 December 2020

Summary

  • The MJA–Lancet Countdown on health and climate change was established in 2017, and produced its first Australian national assessment in 2018 and its first annual update in 2019. It examines indicators across five broad domains: climate change impacts, exposures and vulnerability; adaptation, planning and resilience for health; mitigation actions and health co‐benefits; economics and finance; and public and political engagement.
  • In the wake of the unprecedented and catastrophic 2019–20 Australian bushfire season, in this special report we present the 2020 update, with a focus on the relationship between health, climate change and bushfires, highlighting indicators that explore these linkages.
  • In an environment of continuing increases in summer maximum temperatures and heatwave intensity, substantial increases in both fire risk and population exposure to bushfires are having an impact on Australia’s health and economy. As a result of the “Black Summer” bushfires, the monthly airborne particulate matter less than 2.5 μm in diameter (PM2.5) concentrations in New South Wales and the Australian Capital Territory in December 2019 were the highest of any month in any state or territory over the period 2000–2019 at 26.0 μg/m3 and 71.6 μg/m3 respectively, and insured economic losses were $2.2 billion.
  • We also found growing awareness of and engagement with the links between health and climate change, with a 50% increase in scientific publications and a doubling of newspaper articles on the topic in Australia in 2019 compared with 2018. However, despite clear and present need, Australia still lacks a nationwide adaptation plan for health. As Australia recovers from the compounded effects of the bushfires and the coronavirus disease 2019 (COVID‐19) pandemic, the health profession has a pivotal role to play. It is uniquely suited to integrate the response to these short term threats with the longer term public health implications of climate change, and to argue for the economic recovery from COVID‐19 to align with and strengthen Australia’s commitments under the Paris Agreement.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 University of Sydney, Sydney, NSW
  • 2 Macquarie University, Sydney, NSW
  • 3 Institute for Global Health, University College London, London, UK
  • 4 Queensland University of Technology, Brisbane, QLD
  • 5 University Centre for Rural Health, University of Sydney, Sydney, NSW
  • 6 Australian Institute of Health Innovation, Macquarie University, Sydney, NSW
  • 7 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS
  • 8 Monash Sustainable Development Institute, Monash University, Melbourne, VIC


Correspondence: ying.zhang@sydney.edu.au

Acknowledgements: 

We thank Robert Fawcett, John Nairn, and Elizabeth Ebert (from the Australian Bureau of Meteorology) for indicators 1.1 and 1.2. We thank Yang Liu (Emory University) and Bryan Vu (Emory University) for the Australian data used for indicator 1.3. Finally, we thank Marina Romanello (University College London) and Bradley Graves (Macquarie University) for assistance with visualisation of the indicator 1.3 data.

Competing interests:

No relevant disclosures.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

A guide for medical practitioners transitioning to an encore career or retirement

Chanaka Wijeratne and Joanne Earl
Med J Aust 2021; 214 (1): . || doi: 10.5694/mja2.50870
Published online: 30 November 2020

Controlling the exit from work and accumulating multiple resources early predict adjustment to retirement

The traditional approach to leaving a career in medicine has been informal. The fact that about 10% of medical practitioners in Australia are aged 65 years or over1 — a seemingly natural consequence of increased life expectancy, improved quality of life and fluctuations in financial markets — highlights the need for a more methodical process for leaving medicine.


  • 1 University of Notre Dame Australia, Sydney, NSW
  • 2 Royal North Shore Hospital, Sydney, NSW
  • 3 Macquarie University, Sydney, NSW



Acknowledgements: 

We have received funding from the Avant Foundation to develop an online educational program for medical practitioners transitioning to retirement. The funding source has had no role in the planning or writing of this article.

Competing interests:

No relevant disclosures.

  • 1. Australian Institute of Health and Welfare. Medical practitioners workforce 2015 [Cat. No. WEB 140]. https://www.aihw.gov.au/reports/workforce/medical-practitioners-workforce-2015/contents/who-are-medical-practitioners (viewed Nov 2020).
  • 2. Medical Board Australia. Professional Performance Framework. https://www.medicalboard.gov.au/Registration/Professional-Performance-Framework.aspx (viewed Nov 2020).
  • 3. Earl JK, Muratore AM, Leung C, Yu TW. Career interventions: retirement. In: Hartung PJ, Savickas ML, Walsh WB; editors. APA handbook of career intervention. Volume 2, applications. American Psychological Association, 2015; pp 535–548.
  • 4. Tsugawa Y, Newhouse JP, MacArthur JD, et al. Physician age and outcomes in elderly patients in hospital in the US: observational study. BMJ 2017; 357: 1797.
  • 5. Thomas LA, Milligan E, Tibble H, et al. Health, performance and conduct concerns among older doctors: a retrospective cohort study of notifications received by medical regulators in Australia. J Patient Saf Risk Manag 2018; https://doi.org/10.1177/2516043518763181
  • 6. Wijeratne C, Earl JK, Peisah C, et al. Professional and psychosocial factors affecting the intention of Australian medical practitioners. Med J Aust 2017; 206: 209–214. https://www.mja.com.au/journal/2017/206/5/professional-and-psychosocial-factors-affecting-intention-retire-australian
  • 7. Wijeratne C, Peisah C, Earl JK, Luscombe G. Occupational determinants of successful ageing in older physicians. Am J Geriat Psychiatry 2018; 26: 200–208.
  • 8. Pannor Silver M, Hamilton AD, Biswas A, Warrick NI. A systematic review of physician retirement planning. Hum Resour Health 2016; 14: 67.
  • 9. Pannor Silver M, Williams SA. Reluctance to retire: a qualitative study on work identity, intergenerational conflict and retirement in academic medicine. Gerontologist 2018; 58: 320–330.
  • 10. Topa G, Moriano JA, Depolo M, et al. Antecedents and consequences of retirement planning and decision making: A meta‐analysis and model. J Vocational Behav 2009; 75: 38–55.
  • 11. Wong J, Earl JK. Towards an integrated model of individual, psychosocial and organisational predictors of retirement adjustment. J Vocational Behav 2009; 75: 1–13.
  • 12. Leung CSY, Earl JK. Retirement resources inventory: construction, factor structure and psychometric properties. J Vocational Behav 2012; 2: 171–182.
  • 13. Climent‐Rodríguez JA, Navarro‐Abal Y, López‐López MJ, et al. Grieving for job loss and its relation to the employability of older jobseekers. Front Psychol 2019; 10: 366.
  • 14. Peisah C. Successful ageing for psychiatrists. Austral Psychiatry 2016; 24: 126–130.
  • 15. Jeste D. Successful aging of physicians. Am J Geriatr Psychiatry 2018; 26: 209–211.
  • 16. Saver JL. Best practices in assessing aging physicians for professional competency. JAMA 2020; 323: 127–129.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Superspreaders, asymptomatics and COVID‐19 elimination

David Kault
Med J Aust 2020; 213 (10): . || doi: 10.5694/mja2.50835
Published online: 16 November 2020

Lifting lockdown when numbers are low but not zero means that superspreaders may remain, leading to a further wave of the epidemic

Superspreaders are a well known feature of some infectious diseases.1,2 Clearly, differing social roles will mean some infected people are more likely than others to spread a disease.3 For coronavirus disease 2019 (COVID‐19), biological factors are also important, as there may be a million‐fold variation in the viral load in secretions.4 Measurement of the number of secondary cases from a given primary case has shown that superspreading may be more important in COVID‐19 than in many other infections.5,6,7,8

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • James Cook University, Townsville, QLD


Correspondence: david.kault@jcu.edu.au

Competing interests:

No relevant disclosures.

  • 1. Galvani A, May RM. Dimensions of superspreading. Nature 2005; 438: 293–295.
  • 2. Lloyd‐Smith JO, Schreiber SJ, et al. Superspreading and the effect of individual variation on disease emergence. Nature 2005; 438: 355–359.
  • 3. Zimmer C. Most people with coronavirus won't spread it. why do a few infect many? New York Times 2020; 30 June. https://www.nytim​es.com/2020/06/30/scien​ce/how-coron​avirus-sprea​ds.html (viewed Aug 2020).
  • 4. Gongalsky M. Early detection of superspreaders by mass group pool testing can mitigate COVID‐19 pandemic [preprint]. MedRXiv 2020; https://doi.org/10.1101/2020.04.22.20076166.
  • 5. Endo A, Abbott S, Kucharski AJ, Funk S. Estimating the overdispersion in COVID‐19 transmission using outbreak sizes outside China [preprint]. Wellcome Open Res 2020; https://wellc​omeop​enres​earch.org/artic​les/5-67.
  • 6. Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID‐19: a mathematical modelling study. Lancet Infect Dis 2020; 20: 553–558.
  • 7. Qifang Bi, Yongshen Wu, Mei Shujiang, et al. Epidemiology and transmission of COVID‐19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 2020; 20: P911–P919.
  • 8. Lau MSY, Grenfell B, Nelson K, Lopman B. Characterizing super‐spreading events and age‐specific infectivity of COVID‐19 transmission in Georgia, USA [preprint]. MedRXiv 2020; https://doi.org/10.1101/2020.06.20.20130476.
  • 9. Feller W. Probability theory and its applications. Vol 1. 2nd ed. Wiley, 1961.
  • 10. Kimmel M, Axelrod D. Branching processes in biology: interdisciplinary applied mathematics. Vol. 19. Springer, 2001.
  • 11. Kault D. Superspreaders help covid‐19 elimination [preprint]. MedRXiv 2020; https://doi.org/10.1101/2020.04.19.20071761.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

COVID‐19, children and schools: overlooked and at risk

Zoë Hyde
Med J Aust 2020; 213 (10): . || doi: 10.5694/mja2.50823
Published online: 16 November 2020

Children may be more susceptible than originally thought and could play a role in community transmission

An early cause for hope in the coronavirus disease 2019 (COVID‐19) pandemic was the observation that children are much less likely to experience severe illness than adults.1 This remains true, but has created a perception that children are less susceptible to infection and do not play a substantial role in transmission. In Australia, this perception has been reinforced by assurances from the Prime Minister that schools are safe and that physical distancing is unnecessary in this setting.2 However, emerging research suggests greater caution is needed.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • Western Australian Centre for Health and Ageing, University of Western Australia, Perth, WA


Correspondence: zoe.hyde@uwa.edu.au

Competing interests:

I am supported by funding from an Australian competitive grant (National Health and Medical Research Council grant 1150337).

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Mental health and COVID‐19: are we really all in this together?

Patrick McGorry
Med J Aust 2020; 213 (10): . || doi: 10.5694/mja2.50834
Published online: 9 November 2020

The pandemic is a vast, expanding disaster with no end in sight, producing chronic stress, disruption, and multiple losses

The coronavirus disease 2019 (COVID‐19) pandemic has been a once‐in‐100‐years event. The scale of the disaster overshadows all others in living memory. Most disasters are focal and time‐limited. This one will span a considerable period of time and the economic impact will last years. This means the mental health effects will be deeper and more sustained than in other disasters. A survey during the first month of the pandemic in Australia assessed the nation's “temperature” early, as reported in this issue of the Journal.1 This survey and other information2,3 confirm that the initial mental health impact has been severe, and worse may be coming. Scientific models predicted that Australia would face a second curve of mental ill health and suicide,4,5 and this has now clearly arrived. We have been willing to turn our society and lives upside down to flatten the COVID‐19 curve. The same commitment is now required to flatten the mental health curve.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Orygen, Melbourne, VIC
  • 2 Centre for Youth Mental Health, the University of Melbourne, Melbourne, VIC


Correspondence: pmcgorry@unimelb.edu.au

Acknowledgements: 

I am supported by a National Health and Medical Research Council Senior Principal Research Fellowship (1155508).

Competing interests:

No relevant disclosures.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Understanding the diagnosis of prostate cancer

Xuan Rui S Ong, Dominic Bagguley, John W Yaxley, Arun A Azad, Declan G Murphy and Nathan Lawrentschuk
Med J Aust 2020; 213 (9): . || doi: 10.5694/mja2.50820
Published online: 2 November 2020

Summary

  • Prostate cancer continues to be the most commonly diagnosed cancer, and the second leading cause of cancer death among Australian men.
  • Prostate‐specific antigen testing is personalised (not dichotomous in nature) and its interpretation should take into account the patient's age, symptoms, previous results and medication (eg, 5‐α reductase inhibitors such as dutasteride).
  • Multiparametric magnetic resonance imaging of the prostate has been proven to have a 93% sensitivity for detecting clinically significant prostate cancer. It has the potential to decrease unnecessary prostate biopsies by around 27%.
  • International Society of Urological Pathology (ISUP) grade 1 (Gleason score 6) has been shown to have very little, if any, risk of metastasis
  • ISUP grade 1 (Gleason score 3 +3 = 6) and low percentage ISUP grade 2 (Gleason score 3 + 4 [< 10%] = 7) can be offered active surveillance. The goal of active surveillance is to defer treatment but is still curative when required.
  • With better imaging (magnetic resonance imaging and emerging prostate‐specific membrane antigen positron emission tomography–computed tomography) and transperineal prostate biopsy, more men can be offered screening after discussion of risks and benefits, knowing that overdiagnosis has been minimised and radical treatment is reserved for only the most aggressive disease.

  • 1 EJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, VIC
  • 2 University of Melbourne, Melbourne, VIC
  • 3 University of Queensland, Brisbane, QLD
  • 4 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 5 Peter MacCallum Cancer Centre, Melbourne, VIC


Correspondence: lawrentschuk@gmail.com

Competing interests:

No relevant disclosures.

  • 1. Roberts MJ, Papa N, Perera M, et al. A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. BJU Int 2019; 124 (Suppl 1): 31–36.
  • 2. Australian Institute of Health and Welfare. Cancer in Australia 2019 (Cancer Series No. 119; Cat. No. CAN 123). Canberra: AIHW, 2019. https://www.aihw.gov.au/getmedia/8c9fcf52-0055-41a0-96d9-f81b0feb98cf/aihw-can-123.pdf.aspx?inline=true (viewed Aug 2020).
  • 3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. J Urol 2017; 197 (2 Suppl): S148–S152.
  • 4. Stamey TA, Yang N, Hay AR, et al. Prostate‐specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.
  • 5. Lilja H, Ulmert D, Vickers AJ. Prostate‐specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268–278.
  • 6. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate‐specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–2246.
  • 7. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate‐specific antigen compared with median prostate‐specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67: 316–320.
  • 8. Litchfield MJ, Cumming RG, Smith DP, et al. Prostate‐specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Med J Aust 2012; 196: 395–398. https://www.mja.com.au/journal/2012/196/6/prostate-specific-antigen-levels-men-aged-70-years-and-over-findings-champ-study.
  • 9. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate‐specific antigen in a community‐based population of healthy men. Establishment of age‐specific reference ranges. JAMA 1993; 270: 860–864.
  • 10. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age‐specific reference ranges for serum prostate‐specific antigen in black men. N Engl J Med 1996; 335: 304–310.
  • 11. Partin AW, Criley SR, Subong EN, et al. Standard versus age‐specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol 1996; 155: 1336–1339.
  • 12. DeAntoni EP, Crawford ED, Oesterling JE, et al. Age‐ and race‐specific reference ranges for prostate‐specific antigen from a large community‐based study. Urology 1996; 48: 234–239.
  • 13. Anderson JR, Strickland D, Corbin D, et al. Age‐specific reference ranges for serum prostate‐specific antigen. Urology 1995; 46: 54–57.
  • 14. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–1095.
  • 15. Borer JG, Sherman J, Solomon MC, et al. Age specific prostate specific antigen reference ranges: population specific. J Urol 1998; 159: 444–448.
  • 16. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate‐specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8: 21–25.
  • 17. Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha‐reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868–74.
  • 18. Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5α‐reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868–874.
  • 19. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128–1133.
  • 20. Helfand BT, Anderson CB, Fought A, et al. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology 2009; 74: 177–183.
  • 21. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154 (2 Pt 1): 407–413.
  • 22. Neal DE, Jr., Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992; 20: 105–111.
  • 23. Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int 2017; 119: 225–233.
  • 24. Vickers AJ, Brewster SF. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol 2012; 5: 162–168.
  • 25. Pannek J, Rittenhouse HG, Chan DW, et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159: 1238–1242.
  • 26. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate‐specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542–1547.
  • 27. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [‐2] pro‐prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650–1655.
  • 28. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008; 6: 19.
  • 29. Russo GI, Regis F, Castelli T, et al. A systematic review and meta‐analysis of the diagnostic accuracy of Prostate Health Index and 4‐kallikrein panel score in predicting overall and high‐grade prostate cancer. Clin Genitourin Cancer 2017; 15: 429–439.e1.
  • 30. Mottet N, van den Bergh R, Briers E. EAU‐EANM-ESTRO‐ESUR-SIOG guidelines on prostate cancer. Eur Urol 2019; 75: 889–890.
  • 31. Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018; 319: 1901–1913.
  • 32. Prostate Cancer Foundation of Australia and Cancer Council Australia. Clinical practice guidelines for PSA testing and early management of test‐detected prostate cancer. 2015. https://wiki.cancer.org.au/australia/Guidelines:PSA_Testing (viewed Aug 2020).
  • 33. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 2017; 197 (2 Suppl): S200–S207.
  • 34. Patel MI, Kakala B, Beattie K. Teaching medical students digital rectal examination: a randomized study of simulated model vs rectal examination volunteers. BJU Int 2019; 124 (Suppl 1): 14–18.
  • 35. Schröder FH, Kruger AB, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817–1823.
  • 36. Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835–839.
  • 37. Thompson J, Van Leeuwen P, Moses D, et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol 2016; 195: 1428–1435.
  • 38. Ahmed HU, El‐Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389: 815–822.
  • 39. Hu Y, Ahmed HU, Carter T, et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012; 110: 812–820.
  • 40. Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound‐guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562–566.
  • 41. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. N Engl J Med 2018; 378: 1767–1777.
  • 42. Weinreb JC, Barentsz JO, Choyke PL, et al. PI‐RADS prostate imaging ‐ reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16–40.
  • 43. Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI‐RADS version 2 helps preoperatively predict clinically significant cancers. Radiology 2016; 280: 108–116.
  • 44. Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate Imaging‐Reporting and Data System Steering Committee: PI‐RADS v2 status update and future directions. Eur Urol 2019; 75: 385–396.
  • 45. Woo S, Kim SY, Lee J, et al. PI‐RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy‐proven Gleason Score 7 (3+4) prostate cancer. Eur Radiol 2016; 26: 3580–3587.
  • 46. Hansen NL, Barrett T, Kesch C, et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer. BJU Int 2018; 122: 40–49.
  • 47. Wei TC, Lin TP, Chang YH, et al. Transrectal ultrasound‐guided prostate biopsy in Taiwan: A nationwide database study. J Chin Med Assoc 2015; 78: 662–665.
  • 48. Grummet JP, Weerakoon M, Huang S, et al. Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 2014; 114: 384–388.
  • 49. Symons JL, Huo A, Yuen CL, et al. Outcomes of transperineal template‐guided prostate biopsy in 409 patients. BJU Int 2013; 112: 585–593.
  • 50. Yaxley AJ, Yaxley JW, Thangasamy IA, et al. Comparison between target magnetic resonance imaging (MRI) in‐gantry and cognitively directed transperineal or transrectal‐guided prostate biopsies for Prostate Imaging‐Reporting and Data System (PI‐RADS) 3‐5 MRI lesions. BJU Int 2017; 120 (Suppl 3): 43–50.
  • 51. Stefanova V, Buckley R, Flax S, et al. Transperineal prostate biopsies using local anesthesia: experience with 1,287 patients. prostate cancer detection rate, complications and patient tolerability. J Urol 2019; 201: 1121–1126.
  • 52. Grummet J, Gorin MA, Popert R, et al. “TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis 2020; 23: 62–65.
  • 53. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 2017; 197 (2 Suppl): S134–S139.
  • 54. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs – Part B: prostate and bladder tumours. Eur Urol 2016; 70: 106–119.
  • 55. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244–252.
  • 56. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69: 428–435.
  • 57. Ross AE, Marchionni L, Vuica‐Ross M, et al. Gene expression pathways of high grade localized prostate cancer. Prostate 2011; 71: 1568–1577.
  • 58. Ross HM, Kryvenko ON, Cowan JE, et al. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012; 36: 1346–1352.
  • 59. Amin A, Scheltema MJ, Shnier R, et al. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. J Urol 2020; 203: 910–917.
  • 60. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate‐specific membrane antigen PET‐CT in patients with high‐risk prostate cancer before curative‐intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208–1216.
  • 61. Kalapara AA, Nzenza T, Pan HYC, et al. Detection and localisation of primary prostate cancer using (68) gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int 2020; 126: 83–90.
  • 62. Scheltema MJ, Chang JI, Stricker PD, et al. Diagnostic accuracy of 68Ga‐prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET) and multiparametric (mp) MRI to detect intermediate‐grade intra‐prostatic prostate cancer using whole‐mount pathology: impact of the addition of 68Ga‐PSMA PET to mp MRI. BJU Int 2019; 124: 42–49.
  • 63. Donato P, Morton A, Yaxley J, et al. (68)Ga‐PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is (68)Ga‐PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging 2020; 47: 1843–1851.
  • 64. Amin A, Blazevski A, Thompson J, et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross‐sectional study of the additive diagnostic value of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int 2020; 125: 515–524.
  • 65. Rao K, Manya K, Azad A, et al. Uro‐oncology multidisciplinary meetings at an Australian tertiary referral centre–impact on clinical decision‐making and implications for patient inclusion. BJU Int 2014; 114: 50–54.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Pagination

Subscribe to